Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial

Annals of Surgery

Volumn 231, Issue 4, 2000, Pages 449-456

  Vaillant, Jean Christophe ^a   Nordlinger, Bernard ^b   Deuffic, Sylvie ^c   Arnaud, Jean Pierre ^d   Pelissier, Edouard ^e   Favre, Jean Pierre ^f   Jaeck, Daniel ^g   Fourtanier, Gilles ^h   Grandjean, Jean Paul ⁱ   Marre, Philippe ^j   Letoublon, Christian ^k  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c INSERM   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e Clinique Saint Vincent   (France)

^f HÔPITAL DU BOCAGE   (France)

^g HÔPITAL DE HAUTEPIERRE   (France)

^h CHU RANGUEIL   (France)

ⁱ Service de Radiologie   (France)

^j INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^k HÔPITAL MICHALLON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEUM; PROSPECTIVE STUDIES;

EID: 0034029147     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200004000-00001     Document Type: Review

References (34)

1. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials investigators (IMPACT). Lancet 1995; 345:939-944.
2. Moertel CG, Fleming TR, McDonald JS, et al. Levamisole and fluorouracil for surgical adjuvant therapy of colon carcinoma. N Engl J Med 1990; 322:352-358.
3. Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 1989; 16(Suppl 6):83-97.
4. Gilbert JM, Jeffrey I, Evans M, et al. Sites of recurrent tumour after "curative" colorectal surgery: implications for adjuvant therapy. Br J Surg 1984; 71:203-205.
5. Archer SG, Gray BN. Vascularization of small liver metastases. Br J Surg 1989; 76:545-548.
6. Taylor I, Machin D, Mullee M, et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985; 72:359-363.
7. Fielding LP, Hittinger R, Grace RH, et al. Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. Lancet 1992; 340:502-506.
8. Wolmark N, Rockette H, Petrelli N, et al. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer. Proc ASCO 1994; 13:194.
9. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995; 345:349-353.
10. Wereldsma JCJ, Bruggink EDM, Meijer WS, et al. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (Colorectal Adenocarcinoma Trial I). Cancer 1990; 65:425-432.
11. Liver Infusion Meta-analysis Group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997; 89:497-505.
12. Rougier P, Sahmoud T, Nitti D, et al. Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998; 351:1677-1681.
13. Kelsen DP, Saltz L, Cohen AM, et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high-risk colon cancer. Cancer 1994; 74:2224-2233.
14. Graf W, Westlin JE, Pahlman L, et al. Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study. Int J Colorectal Dis 1994; 9:35-39.
15. Scheithauer W, Kornek GV, Marczell A, et al. Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma. Br J Cancer 1998; 77:1349-1354.
16. Hillan K, Nordlinger B, Ballet F, et al. The healing of colonic anastomoses after early intraperitoneal chemotherapy: an experimental study in rats. J Surg Res 1988; 44:166-171.
17. Schilsky RL, Choi KE, Grayhack J, et al. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990; 8:2054-2061.
18. Scheithauer W, Kornek G, Rosen H, et al. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonie adenocarcinoma. Eur J Cancer 1995; 31:1981-1986.
19. Sugarbaker PH, Gianola FJ, Speyer JL, et al. Prospective randomized trial of intravenous vs. intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985; 12(Suppl 4):101-111.
20. Gyves J. Pharmacology of intraperitoneal infusion 5-fluorouracil and mitomycin-C. Semin Oncol 1985; 12(Suppl 4):29-32.
21. Nordlinger B, Panis Y, Puts JP, et al. Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. Dis Colon Rectum 1991; 34:658-663.
22. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 1985; 12:23-28.
23. Sugarbaker PH, Graves T, DeBruijn EA, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990; 50:5790-5794.
24. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62:1-11.
25. Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 1977; 61:1307-1317.
26. Salmon SE. Kinetics of minimal residual disease. Recent Results Cancer Res 1979; 67:5-15.
27. Panis Y, Ribeiro J, Chretien Y, et al. Dormant liver metastases: an experimental study. Br J Surg 1992; 79:221-223.
28. Eggermont AM, Steller EP, Sugarbaker PH. Laparotomy enhances intraperitoneal tumor growth and abrogates the antitumor effects of interleukin-2 and lymphokine-activated killer cells. Surgery 1987; 102:71-78.
29. Solomon MJ, Egan M, Roberts RA, et al. Incidence of free colorectal cancer cells on the peritoneal surface. Dis Colon Rectum 1997; 40: 1294-1298.
30. Wiggers T, Jeekel J, Arends JW, et al. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 1988; 75:409-415.
31. Los G, McVie JG. Experimental and clinical status of intraperitoneal chemotherapy. Eur J Cancer 1990; 26:755-762.
32. Jacquet P, Stuart OA, Dalton R, et al. Effect of intraperitoneal chemotherapy and fibrinolytic therapy on tumor implantation in wound sites. J Surg Oncol 1996; 62:128-134.
33. Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228:347-354.
34. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol 1990; 8:1466-1475.